title: Expression of Membrane Complement Regulatory Proteins Crry and CD55 in Normal Rats.
abstract: Some anticancer therapeutic antibodies are designed to act through complement-dependent cytotoxicity (CDC). It has been reported that there are many membrane complement regulatory proteins (mCRPs) that inhibit CDC. In the present study, we examined the expression of two mCRPs, the complement receptor 1-related gene/protein Y (Crry) and the decay-accelerating factor CD55, in three normal rats by immunohistochemistry. Crry and CD55 were detected widely in rat organs and tissues. Crry was found mainly in the urinary, digestive, respiratory, immunohematopoietic, circulatory and neuroendocrine systems. CD55 was found in the urinary, digestive and neuroendocrine systems. However, the two molecules were expressed in separate cells within the same organ. These results suggest that the distribution of mCRPs is related to the strict regulation of CDC activation in these organs and tissues and that the two molecules have a nonoverlapping expression pattern, a fact indicating specific roles in CDC regulation.
authors.affiliation: Research Division, Chugai Pharmaceutical Co., Ltd., 200 Kajiwara, Kamakura, Kanagawa 247-8530, Japan.
authors.forename: Chie
authors.initials: C
authors.lastname: Kato
authors.forename: Atsuhiko
authors.initials: A
authors.lastname: Kato
authors.forename: Kenji
authors.initials: K
authors.lastname: Adachi
authors.forename: Etsuko
authors.initials: E
authors.lastname: Fujii
authors.forename: Kaori
authors.initials: K
authors.lastname: Isobe
authors.forename: Takeshi
authors.initials: T
authors.lastname: Watanabe
authors.forename: Tsuneo
authors.initials: T
authors.lastname: Ito
authors.forename: Masami
authors.initials: M
authors.lastname: Suzuki
keywords: CD55; Crry; membrane complement regulatory proteins; rat
references.citation: Mol Immunol. 2003 Sep;40(2-4):145-53
references.pmid: 12914820
references.citation: Clin Immunol. 2006 Feb-Mar;118(2-3):127-36
references.pmid: 16338172
references.citation: Mol Immunol. 2010 Nov-Dec;48(1-3):9-13
references.pmid: 20869772
references.citation: Int Immunopharmacol. 2001 Mar;1(3):445-59
references.pmid: 11367529
references.citation: J Toxicol Pathol. 2013 Mar;26(1):41-9
references.pmid: 23723567
references.citation: J Toxicol Sci. 2002 Aug;27(3):165-72
references.pmid: 12238140
references.citation: J Immunol. 1994 Mar 15;152(6):3032-8
references.pmid: 8144902
references.citation: Immunology. 1999 Jul;97(3):374-84
references.pmid: 10447757
references.citation: Annu Rev Immunol. 1989;7:35-58
references.pmid: 2469439
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):278-87
references.pmid: 22437872
references.citation: Immunology. 1994 Mar;81(3):444-51
references.pmid: 7515849
references.citation: Nat Immunol. 2010 Sep;11(9):785-97
references.pmid: 20720586
references.citation: Cell Mol Life Sci. 2002 Feb;59(2):220-9
references.pmid: 11915940
references.citation: Annu Rev Immunol. 1991;9:431-55
references.pmid: 1910685
references.citation: J Immunol. 1998 Nov 15;161(10):5695-703
references.pmid: 9820551
references.citation: J Exp Med. 1995 Jan 1;181(1):151-9
references.pmid: 7528766